| Literature DB >> 35237648 |
Lorenzo Ripamonti1, Angelo Guttadauro1,2, Giulia Lo Bianco1, Maria Rennis1, Matteo Maternini2, Gerardo Cioffi3, Marco Chiarelli4, Matilde De Simone5, Ugo Cioffi5, Francesco Gabrielli1,2.
Abstract
Obstructed defecation syndrome (ODS) is a form of constipation that influences the quality of life in most patients and is an important health care issue. In 2004 Longo introduced a minimal invasive trans-anal approach known as Stapled Trans-Anal Rectal Resection (STARR) in order to correct mechanical disorders such as rectocele or rectal intussusception, two conditions present in more than 90% of patients with ODS. Considering the lack of a common view around ODS and STARR procedure. the aim of our study is to review the literature about preoperative assessment, operative features and outcomes of the STARR technique for the treatment of ODS. We performed a systematic search of literature, between January 2008 and December 2020 and 24 studies were included in this review. The total number of patients treated with STARR procedure was 4,464. In conclusion STARR surgical procedure has been proven to be safe and effective in treating symptoms of ODS and improving patients Quality of Life (QoL) and should be taken in consideration in the context of a holistic and multi modal approach to this complex condition. International guidelines are needed in order to optimize the diagnostic and therapeutic process and to improve outcomes.Entities:
Keywords: QOL; international guidelines; obstructed defecation syndrome; outcomes; stapled trans-anal rectal resection; surgical procedure
Year: 2022 PMID: 35237648 PMCID: PMC8882820 DOI: 10.3389/fsurg.2022.790287
Source DB: PubMed Journal: Front Surg ISSN: 2296-875X
PICOS table.
|
|
|
|---|---|
| Interventions | STARR technique using PPH01, PPH03, TST, STR10, CCS30, STR5G |
| Comparisons | - |
| Outcomes | Preoperative assessment, operative features and post-operative complications and long-term outcomes of the STARR technique for the treatment of ODS |
| Study design | Retrospective, prospective and randomized control trials available in full text and published in English language. Case reports were excluded |
Figure 1Risk of bias according to RoB 2 tool for RCT.
Figure 2Risk of bias according to ROBINS-I tool.
Figure 3PRISMA 2020 flow diagram for study selection.
Studies.
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
| Altomare et al. ( | Retrospective | 21 | 21/0 | 58 (32–76) | ||
| Boccasanta et al. ( | RCT | 50 | 50/0 | 54.8 (27–77) | - | N |
| 50 | 50/0 | 57.1 (31–74) | - | |||
| Giarratano et al. ( | 260 | 260/0 | 54 (20–78) | Y | Y | |
| Guttadauro et al. ( | Retrospective | 450 | 387/63 | 56 (28–77) | Y | - |
| Hasan and Hasan ( | Prospective | 40 | 40/0 | 45.7 (30–63) | Y | Y |
| Madbouly et al. ( | Retrospective | 46 | 30/16 | 48.4 (29–68) | Y | - |
| Madbouly et al. ( | Randomized | 56 | 38/18 | 75 (70–85) | Y | Y |
| Mari et al. ( | Retrospective | 96 | 93/3 | 55 (33–82) | Y | - |
| Masoni et al. ( | 187 | 182/5 | 56 (33–85) | Y | Y | |
| Naldini et al. ( | Retrospective | 45 | 45/0 | 50.1 (24–79) | - | |
| Ohazuruike et al. ( | Retrospective | 23 | 19/4 | 52.6 | Y | Y |
| Panicucci et al. ( | Prospective | 54 | 52/2 | 54.25 (28–77) | Y | - |
| Patel et al. ( | Retrospective | 37 | 37/0 | 52.9 (31–74) | Y | Y |
| Ram et al. ( | 30 | 29/1 | 67.1 (50–75) | - | - | |
| Ren et al. ( | Retrospective | 50 | 43/7 | 53 (22–82) | Y | - |
| Ribaric et al. ( | Prospective | 100 | 98/2 | 60 (27–82) | Y | Y |
| Savastano et al. ( | Prospective | 32 | 32/0 | 54 | Y | - |
| 32 | 32/0 | 60.5 | ||||
| Schwandner et al. ( | Prospective | 379 | 296/83 | 57.8 | Y | Y |
| Song et al. ( | Retrospective | 58 | 50/8 | 54 (19–85) | Y | Y |
| Stuto et al. ( | Prospective | 2,171 | 1,653/358 | 56.28 (20–96) | - | - |
| Wolff et al. ( | Prospective | 52 | 52/0 | 64 (20–87) | Y | Y |
| Zehler et al. ( | Prospective | 20 | 19/1 | 60.5 (45.3–78.6) | Y | - |
| Zhang et al. ( | Retrospective | 50 | 50/0 | 53.7 (30–70) | Y | Y |
| Zhang et al. ( | Prospective | 75 | 75/0 | 54.3 (29–75) | Y | Y |
RCT, randomized controlled trial; Y, yes; N, not; F, female; M, male.
Preoperative evaluation.
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| |
| Altomare et al. ( | Y | Y | Y | N | N | N | N | N | N |
| Boccasanta et al. ( | Y | Y | Y | ||||||
| Giarratano et al. ( | Y | Y | Y | N | N | N | N | N | N |
| Guttadauro et al. ( | Y | Y | Y | N | N | N | N | N | N |
| Hasan and Hasan ( | Y | N | Y | N | N | N | N | N | N |
| Madbouly et al. ( | Y | Y | Y | N | N | N | N | N | N |
| Madbouly et al. ( | Y | N | N | N | N | N | N | N | N |
| Mari et al. ( | Y | Y | Y | N | N | N | N | Y | N |
| Masoni et al. ( | Y | Y | N | N | N | N | N | Y | N |
| Naldini et al. ( | |||||||||
| Ohazuruike et al. ( | Y | Y | Y | N | N | N | N | N | N |
| Panicucci et al. ( | Y | Y | Y | N | N | N | Y | N | N |
| Patel et al. ( | Y | Y | Y | Y | Y | Y | N | N | |
| Ram et al. ( | Y | Y | Y | Y | N | N | N | N | N |
| Ren et al. ( | Y | N | Y | N | N | N | N | N | N |
| Ribaric et al. ( | Y | N | Y | N | N | N | N | Y | N |
| Savastano et al. ( | Y | Y | Y | Y | |||||
| Schwandner et al. ( | Y | Y | Y | ||||||
| Song et al. ( | Y | Y | Y | Y | N | N | N | N | Y |
| Stuto et al. ( | Y | Y | N | N | N | N | Y | N | N |
| Wolff et al. ( | N | Y | Y | N | N | N | Y | Y | N |
| Zehler et al. ( | Y | Y | Y | N | N | N | Y | N | |
| Zhang et al. ( | Y | Y | Y | N | N | N | N | N | Y |
| Zhang et al. ( | Y | Y | Y | N | N | N | N | N | Y |
Y, yes; N, not; US, ultrasound; MRI, magnetic resonance imaging.
Score for preoperative evaluation.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Altomare et al. ( | 16.00 | ||||
| Boccasanta et al. ( | 20.60 | Y | |||
| 20.88 | |||||
| Giarratano et al. ( | 19.00 | Y | |||
| Guttadauro et al. ( | 14.10 | Y | |||
| Hasan and Hasan ( | 14.20 | Y | |||
| Madbouly et al. ( | 11.56 | 52.60 | |||
| Madbouly et al. ( | 17.40 | 11.10 | 55.10 | ||
| Mari et al. ( | 15.80 | Y | |||
| Masoni et al. ( | 15.80 | Y | |||
| Naldini et al. ( | 17.26 | ||||
| Ohazuruike et al. ( | 18.20 | 17.00 | Y | ||
| Panicucci et al. ( | 21.38 | 19.49 | Y | ||
| Patel et al. ( | 11.10 | Y | |||
| Ram et al. ( | 17.10 | Y | |||
| Ren et al. ( | 13.96 | Y | |||
| Ribaric et al. ( | 15.65 | Y | |||
| Savastano et al. ( | 13.00 | 12.00 | - | ||
| 15.00 | 14.00 | ||||
| Schwandner et al. ( | 11.14 | 13.00 | - | ||
| Song et al. ( | 17.60 | Y | |||
| Stuto et al. ( | 16.70 | 15.60 | 51 | Y | |
| Wolff et al. ( | 16.00 | 12.50 | Y | ||
| Zehler et al. ( | 8.00 | 4.00 | 5.00 | Y | |
| Zhang et al. ( | 17.54 | 15.58 | 12.22 | 47.78 | Y |
| Zhang et al. ( | 18.39 | 15.57 | 13.69 | 44.45 | Y |
ODS, Obstructed Defecation Syndrome; SS, Symptoms Severity; PAC-QoL, Patient Assessment of Constipation Quality of life questionnaire.
Surgical feature.
|
|
|
|
|
|
|
|---|---|---|---|---|---|
| Altomare et al. ( | - | - | PPH01 | - | - |
| Boccasanta et al. ( | Cefotaxime + metronizadole | Spinal | PPH01 | 42.4 | 3.2 |
| CCS30 | 52.2 | 3.5 | |||
| Giarratano et al. ( | Cefotaxime | General/spinal | PPH01/PPH03 | 42.0 | 3 |
| Guttadauro et al. ( | Cefotaxime + metronidazole | Spinal | PPH01 | 30.2 | 1 |
| Hasan and Hasan ( | Y | General/spinal | PPH01 | 35.0 | 1.7 |
| Madbouly et al. ( | - | General | PPH01 | 48.4 | 1 |
| Madbouly et al. ( | - | 45.4 | 1 | ||
| Mari et al. ( | Metronidazole + ciprofloxacin/cefotaxime | General/spinal | CCS30 | - | - |
| Masoni et al. ( | Metronidazole + ciprofloxacin or metronidazole + cefotaxime | General | CCS30 | 48.0 | 3 |
| Naldini et al. ( | - | General/spinal | TST | 30.9 | 2.6 |
| Ohazuruike et al. ( | Metronidazole + cefamezin | General | PPH01 | 28.0 | 2 |
| Panicucci et al. ( | Metronidazole + cefamezin | General/spinal | PPH01/CCS30 | - | - |
| Patel et al. ( | Y | General | STR10 | - | 1 |
| Ram et al. ( | Metronidazole + ceftriaxone | General/spinal | PPH01 | 40.0 | 2 |
| Ren et al. ( | Y | General/spinal | TST | 21.0 | 5 |
| Ribaric et al. ( | Y | General/spinal | CCS30 | 43.8 | 4.46 |
| Savastano et al. ( | Y | Spinal | PPH01 | 28.0 | 2 |
| CCS30 | 43.0 | 4 | |||
| Schwandner et al. ( | - | General/spinal | PPH01 | 40.0 | 5.5 |
| Song et al. ( | Metronidazole + cefotaxime | Spinal | PPH01 | 35.1 | 3.91 |
| Stuto et al. ( | Y | General/spinal | PPH01/CCS30 | 95.0 | 3.54 |
| Wolff et al. ( | Metronidazole + cefamandole | General/spinal | STR5G | 45.0 | 5 |
| Zehler et al. ( | Y | General/spinal | PPH01 | - | 8 |
| Zhang et al. ( | Y | Spinal | PPH01 | 28.0 | - |
| Zhang et al. ( | Y | Spinal | PPH01 | 30.0 | 5 |
LOS, lenght of stay; min, minutes; d, days; Y, yes.
Postoperative complications.
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| Altomare et al. ( | 1 (0.1) | 2 (0.3) | ||||||
| Boccasanta et al. ( | 2 (4) | 0 | 17 (34) | |||||
| 0 | 0 | 7 (14) | ||||||
| Giarratano et al. ( | 10 (4) | 18 (6.8) | 12 (4.5) | 1 (0.4) | 1 (0.4) | 1 (0.4) | 27 (10.3) | |
| Guttadauro et al. ( | 0 | 35 (7.8) | 13 (2.9) | 5 (1.1) | 19 (4.2) | 0 | 125 (17.8) | |
| Hasan and Hasan ( | 4 (10) | 2 (5) | 4 (10) | 0 | 0 | 0 | 0 | 16 (40) |
| Madbouly et al. ( | 1 (2.2) | 1 (2.2) | 0 | 0 | 0 | 0 | ||
| Madbouly et al. ( | 3 (2.4) | 2 (1.78) | 0 | 8 (7.14) | ||||
| Mari et al. ( | 20 (20.8) | 8 (8.3) | ||||||
| Masoni et al. ( | 4 (2.1) | 1 (0.5) | 12 (6.4) | |||||
| Naldini et al. ( | 11(24.4) | 1 (2.2) | 12 (26.6) | |||||
| Ohazuruike et al. ( | 1 (4) | 11 (47.8) | ||||||
| Panicucci et al. ( | ||||||||
| Patel et al. ( | 5 (13.5) | 1 (2.7) | 6 (16.2) | 0 | 0 | 2 (5.4) | 0 | 2 (5.4) |
| Ram et al. ( | 3(10) | 0 | ||||||
| Ren et al. ( | 12 (24) | 1 (0.5) | 5 (10) | |||||
| Ribaric et al. ( | 1(1) | 2(2) | 5(5) | |||||
| Savastano et al. ( | 4 (12.5) | 29 (29.8) | ||||||
| 1(3.12) | 2 (6.25) | 6 (18.7) | ||||||
| Schwandner et al. ( | 2 (0.5) | 4 (1.1) | 11 (2.9) | 27 (7.1) | 4 (1.1) | 6 (1.6) | ||
| Song et al. ( | 1 (1.7) | 7 (12) | 11 (18.9) | |||||
| Stuto et al. ( | 209 (9.63) | 79 (3.6) | 74 (3.4) | 1 (0.005) | 567 (26.1) | |||
| Wolff et al. ( | 2 (3.07) | 1 (1.6) | 2 (2.9) | |||||
| Zehler et al. ( | 2 (2.9) | 1 (1.4) | 0 | |||||
| Zhang et al. ( | 2 (4) | 2 (4) | 4 (8) | 0 | 0 | 0 | 0 | 21 (42) |
| Zhang et al. ( | 4 (4.65) | 6 (6.9) | 30 (35) |
Long term outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Altomare et al. ( | 12 | ||||||||||||||
| Boccasanta et al. ( | 6 (12) | 3.52 | |||||||||||||
| 0 | 3.14 | ||||||||||||||
| Giarratano et al. ( | 10 (4) | 9 | |||||||||||||
| Guttadauro et al. ( | 0 | 12 (5.3) | 0 | 3.1 | 4.3 | 6.4 | - | - | |||||||
| Hasan and Hasan ( | 4 (10) | 4 (10) | 2 (5) | 1 (2.5) | 2.3 | ||||||||||
| Madbouly et al. ( | 3 (6.5) | 2.2 | 3.7 | 30.3 | 40.9 | ||||||||||
| Madbouly et al. ( | 11 (24) | 6.7 | 10.2 | 14.7 | 20.2 | ||||||||||
| Mari et al. ( | 3 (3.1) | 1 (1) | 1 (1) | 5.2 | 7.4 | ||||||||||
| Masoni et al. ( | 5.2 | ||||||||||||||
| Naldini et al. ( | 3 (6.7) | 4 (8.9) | 2 (4.4) | 4.74 | |||||||||||
| Ohazuruike et al. ( | 5.5 | 4.7 | |||||||||||||
| Panicucci et al. ( | 3 | 4 (7.4) | 5.47 | 6.14 | |||||||||||
| Patel et al. ( | 3 (8.1) | 4.6 | |||||||||||||
| Ram et al. ( | 4 | ||||||||||||||
| Ren et al. ( | 7.28 | 8.10 | |||||||||||||
| Ribaric et al. ( | 5.52 | 0.95 | |||||||||||||
| Savastano et al. ( | 29 (29.8) | 23 (23.7) | 1 | 1 | |||||||||||
| 6 (18.7) | 6 (18.7) | 1 | 1 | ||||||||||||
| Schwandner et al. ( | 6.45 | 6.59 | 0.63 | ||||||||||||
| Song et al. ( | - | 9.6 | |||||||||||||
| Stuto et al. ( | 246 (11.3) | 99 (4.56) | 5 | 0.7 | 2.6 | 22 | |||||||||
| Wolff et al. ( | 7(10.7) | 4(6) | 0 | 5 | 6 | ||||||||||
| Zehler et al. ( | - | 3 | 3 | 2 | 3 | ||||||||||
| Zhang et al. ( | 1 (2) | 5 (10) | 3 (6) | 1 (2) | 5.92 | 5.68 | 4.52 | 8.14 | |||||||
| Zhang et al. ( | 8 (10.7) | 1 (1.3) | 7.49 | 8.55 | 5.99 | 7.07 | 4.59 | 7 | 13.21 |
ODS, Obstructed Defecation Syndrome; SS, Symptoms Severity; PAC-QoL, Patient Assessment of Constipation Quality of life questionnaire; m, months; y, years.